The department of Pharmaceutical Technology and Biopharmacy (Prof. Erik Frijlink) of the Groningen Research Institute of Pharmacy (GRIP) has received a 422K€ grant from EU’s Innovative Medicines Initiative (IMI). The “Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis” (iABC) project aims at the development of new antibiotics to be used in pulmonary diseases. The consortium consists of 19 partners from 7 countries. These groups combine experience and proven expertise and success in microbiology, antibiotic development, clinical trials, endpoints and patient registries. The activities in Groningen will focus on the development of formulations and devices for pulmonary administration of new Beta-lactam antibiotics.
IMI is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
Every two weeks, UG Makers puts the spotlight on a researcher who has created something tangible, ranging from homemade measuring equipment for academic research to small or larger products that can change our daily lives. That is how UG...
As a part of the Jantina Tammes School, the 'Language and AI' theme is an interdisciplinary initiative that aims to encourage collaboration among academics, PhD candidates, students, and industry representatives who share a keen interest in the...
Prof. Moniek Tromp has been appointed Captain of Science of the Chemistry Top Sector by the Minister of Economic Affairs and Climate Policy. As from 1 July 2023, she succeeded Prof. Bert Weckhuysen from Utrecht University.
The UG website uses functional and anonymous analytics cookies. Please answer the question of whether you want to accept
or reject other cookies (such as tracking cookies).
If no choice is made, only basic cookies will be stored. More information